Close

UCB Announces Start of the EXXELERATE™ Clinical Study in Rheumatoid Arthritis Dec 21, 2011 01:00AM
New Data on Patient-Reported Improvements in Quality of Life Measures and Other Clinical Responses in Moderate to Severe Rheumatoid Arthritis Patients Taking Cimzia® (certolizumab pegol) Highlighted Nov 7, 2011 02:00AM
New RAPID 1 Post-Hoc Analysis Showed Early Response to Cimzia® (certolizumab pegol) at Week 12 was Predictive of Week 52 Response Nov 7, 2011 02:00AM
New RAPID 1 Post-Hoc Analysis Showed Early Response to Cimzia® (certolizumab pegol) at Week 12 Was Predictive of Week 52 Response Nov 7, 2011 02:00AM
New Data on Patient-Reported Improvements in Quality of Life Measures and Other Clinical Responses in Moderate to Severe Rheumatoid Arthritis Patients Taking Cimzia® (certolizumab pegol) Highlighted Nov 7, 2011 02:00AM


Nov 7, 2011 02:00AM New Data From REALISTIC Study Showed Cimzia® (certolizumab pegol) Provided Rapid and Sustained Efficacy, Over 28 Weeks, in a Broad Population of Patients With Moderate to Severe Rheumatoid Arthritis
Nov 4, 2011 03:00PM UCB Reinforces Long-Standing Commitment to Rheumatology at American College of Rheumatology 2011 Annual Scientific Meeting
Nov 4, 2011 02:57PM UCB Reinforces Long-Standing Commitment to Rheumatology at American College of Rheumatology 2011 Annual Scientific Meeting
Oct 31, 2011 10:00AM New data on Cimzia® (certolizumab pegol) to be presented at ACG meeting highlights role of inflammatory biomarkers in treatment for moderate to severe Crohn’s disease
Oct 31, 2011 10:00AM New Data on Cimzia® (certolizumab pegol) to be Presented at ACG Meeting Highlights Role of Inflammatory Biomarkers in Treatment for Moderate to Severe Crohn's Disease